pharma · Facioscapulohumeral Muscular Dystrophy (FSHD) · Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) · FULC
Fulcrum Therapeutics
NovaPharmaNews editorial coverage mentioning Fulcrum Therapeutics — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 26 Landsdowne St, Cambridge, Massachusetts 02139, US
- Founded
- 2016
- Employees
- 73
- Programs
- 12
- Drugs
- 8
- Patents
- 11
News & analysis
NovaPharmaNews articles mentioning Fulcrum Therapeutics — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Fulcrum Therapeutics — regulatory, clinical, and market analysis.
Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation
Fulcrum Therapeutics' stock experienced a significant 54% drop following the discontinuation of its sickle cell disease drug, citing regulatory hurdles. This event highlights potential challenges in clinical trial design for the indication.
Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures
A ten-year-old Cambridge-based biotech company is actively seeking a merger or acquisition. This move comes as public markets have shown volatility, impacting biotech valuations.